<![CDATA[Case Study: Selecting Frontline Therapy in Higher-Risk EGFR-Mutant NSCLC With Brain Metastases]]>

Summary

Case study discussing frontline therapy selection for a higher-risk EGFR-mutant NSCLC patient with brain metastases and high disease burden. This is educational content presenting clinical scenarios without trial data, approvals, or material corporate announcements.